Cellistic
Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. We believe that human iPSC technology will help get better therapies to patients faster.
Leveraging more than a decade of iPSC knowledge and experience, we are designing and optimizing proprietary manufacturing platforms that overcome the current complexity and challenges of iPSC-based allogeneic cell therapy development. Our focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development positions us to be the partner of choice for innovative cell therapy developers to commercialize novel advanced therapies.